Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety

PHASE4CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

March 20, 2016

Primary Completion Date

March 5, 2022

Study Completion Date

March 5, 2022

Conditions
Erosive Esophagitis
Interventions
DRUG

Vonoprazan

Vonoprazan fumarate 10 mg or 20 mg capsules

DRUG

Lansoprazole

Lansoprazole 15 mg or 30 mg capsules

Trial Locations (36)

Unknown

Tokatsu Tsujinaka Hospital, Abiko

Hohnodai Hospital National Center For Global Health and Medicine, Ichikawa

Red Cross Matsuyama Hospital, Matsuyama

Kawakubo Clinic, Kama

Hakodate Hospital, Hakodate

Aoyama Medical Clinic, Kobe

Hyogo College Of Medicine, Nishinomiya

KKR Takamatsu Hospital, Takamatsu

Shirane Clinic, Sendai

Tohoku University Hospital, Sendai

Shin-Beppu Hospital, Beppu

Kawasaki Medical University, Kurashiki

Shiga Hospital, Ōtsu

Shiga University Of Medical Science Hospital, Ōtsu

Shimane University Hospital, Izumo

Juntendo University Shizuoka Hospital, Izunokuni

Kohga Hospital, Yaizu

Masuyama Clinic, Ōtawara

Juntendo University Hospital, Bunkyo-ku

Banno Clinic, Ōta-ku

Shimokitazawa Tomo Clinic, Setagaya-ku

National Center For Global Health and Medicine, Shinjyuku-ku

Nippon Medical School Hospital, Shinjyuku-ku

Chihaya Hospital, Fukuoka

Harada Hospital, Fukuoka

Kimura Shiro Clinic, Fukuoka

Kyushu University Hospital, Fukuoka

Mori Clinic, Fukuoka

Hanabata Clinic, Kumamoto

Morinaga Ueno Clinic, Kumamoto

Oki Hospital, Kyoto

Asahigaoka Hospital, Okayama

Kawasaki Hospital, Okayama

Arita Hospital, Ōita

Matsuki Clinic, Shizuoka

Oizumi Medical Clinic, Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT02679508 - Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety | Biotech Hunter | Biotech Hunter